AI-powered trial screening helps community oncology practices identify eligible patients locally, widening access beyond ...

The benefit of daraxonrasib in PDAC may be overstated in RASolute 302 due to informative censoring. The RASolute 302 trial (NCT06625320) in pancreatic cancer has received a lot of attention. The study ...

The first patient has been dosed in MODeFIRe-1 (NCT07745361), a phase 2 study evaluating MRT-2359 in combination with ...

Zanidatamab plus tislelizumab and chemotherapy reduced mortality risk by 28% versus trastuzumab plus chemotherapy, delivering ...

As artificial intelligence (AI) becomes more integrated into clinical trial matching, human oversight remains an important ...

Sustained MRD negativity at 12 months was higher with D-VRd, with similar advantages at 24 and 36 months and a lower rate of ...

Primary endpoint results showed no SSE-FS benefit with radium-223 addition (HR 1.46; 1-sided P=.12), while OS, PFS, and ORR ...

Laila Alkhouli, MD, of Cleveland Children's Clinic outlines critical findings from research evaluating how care teams across ...

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Priority review reflects AZUR-1 meeting its primary end point of meaningful, sustained 12-month cCR in dMMR/MSI-H stage ...

Hearn Jay Cho, MD, explains how immune profiling could inform what impairs T-cell fitness, a crucial consideration when using CAR T-cell therapy or bispecific T-cell engagers. Hearn Jay Cho, MD, PhD, ...

CMS’s survey-based ASP–33.4% rate would reduce Part B drug spend (~$5.1B) and beneficiary cost-sharing ($1.15B in 2027), with ...